氯丙咪嗪,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
1252	*6	The CYP2D66 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D66 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.
1251	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D65 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.
1250	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D64 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.
1249	*3	The CYP2D63 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D63 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.
1248	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D61 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with clomipramine may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Other genetic and clinical factors may also influence treatment related side effects.

等位基因

注释文本

The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.

1251

The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.

1250

The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.

1249

The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.

1248

The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with clomipramine may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Other genetic and clinical factors may also influence treatment related side effects.

id	证据的ID	总结
2376	1184467243	CYP2D6 3 + 4 + 5 + 6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.
2375	1183617418	CYP2D6 4/4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 1/1.
2374	1183616659	CYP2D6 1/4 is associated with increased risk of side effects when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 1/2.
2373	982030065	CYP2D6 4/6 is associated with increased risk of Drug Toxicity when treated with clomipramine and quetiapine in people with Depressive Disorder, Major.
2372	981476405	Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.
2371	1183683989	CYP2D6 poor metabolizers are associated with side effects when treated with clomipramine.
2370	PA166104964	Annotation of DPWG Guideline for clomipramine and CYP2D6
2369	PA166105007	Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6

证据的ID

总结

2376

1184467243

CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.

2375

1183617418

CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.

2374

1183616659

CYP2D6 *1/*4 is associated with increased risk of side effects when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2.

2373

982030065

CYP2D6 *4/*6 is associated with increased risk of Drug Toxicity when treated with clomipramine and quetiapine in people with Depressive Disorder, Major.

2372

981476405

Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.

2371

1183683989

CYP2D6 poor metabolizers are associated with side effects when treated with clomipramine.

2370

PA166104964

Annotation of DPWG Guideline for clomipramine and CYP2D6

2369

PA166105007

Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6

id	类型	评论
1382	Update	Added DPWG guideline as evidence
1381	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1380	Create	Created

类型

1382

Update

Added DPWG guideline as evidence

1381

Update

CA score added as part of scoring system release. LOE assigned following curator review.

1380

Create

Created